Nirvana Life Sciences Inc.

NIRV

CA6546521064

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 15:01:35 2024-05-22 EDT			5-day change	1st Jan Change
0.04 ^CAD	-20.00%		-.--%	+100.00%

04-02	Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
01-02	Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	CI

Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory Board

April 05, 2022 at 09:00 am

Nirvana Life Sciences Inc. announced the appointment of Mr. Andrew Samann to the Company's Advisory Board. Andrew Samann is CEO and Principal Consultant of Orion GMP Solutions.

Latest news about Nirvana Life Sciences Inc.

Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	04-02	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	01-02	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	11-01	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	23-10-27	CI
Nirvana Life Sciences Inc. completed the acquisition of Medsmart Dispensary Inc.	23-07-30	CI
Nirvana Life Sciences Inc. entered into a letter of intent to acquire Medsmart Dispensary Inc. for $0.13 million.	23-06-06	CI
Nirvana Life Sciences Inc. announced that it has received funding	23-05-09	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	23-04-03	CI
Nirvana Life Sciences Inc. Announces Resignation of Chris Hoffmeister from the Board of Directors	23-02-22	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	22-12-30	CI
Nirvana Life Sciences Agrees to Buy Licensed Distributor of Patented, Herbal Treatment for Opiate Addiction	22-11-21	MT
Nirvana Life Sciences Inc. Appoints Sheldon Inwentash to the Company's Board of Directors	22-11-09	CI
Nirvana Life Sciences Inc. Reports Earnings Results for the First Quarter Ended July 31, 2022	22-09-29	CI
Nirvana Life Sciences Inc. Announces Method for Producing MDMA That Reduces Manufacturing Time by Two Thirds	22-09-07	CI
Nirvana Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	22-08-28	CI
Nirvana Life Sciences Inc. Announces Executive Changes	22-08-08	CI
Nirvana Life Sciences Inc. Announces License for A Delivery System for Psychedelic APIs	22-07-06	CI
Nirvana Life Sciences Announces Approval to Build Vancouver Facility from Health Canada	22-06-28	CI
Nirvana Life Sciences Announces Filing of Patent for Novel Isolation of 4-PO-Psilocin Prodrug Compound	22-06-23	CI
Nirvana Life Sciences Announces Patent Filing	22-06-09	CI
Nirvana Life Sciences Inc. Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study	22-06-02	CI
Nirvana Life Sciences Inc. announced that it has received CAD 0.15 million in funding from ThreeD Capital Inc.	22-05-31	CI
Nirvana Life Sciences Inc. Announces the Appointment of Andrew Samann to Advisory Board	22-04-05	CI
Nirvana Life Sciences Inc. Announce Further Progress with Development of Its Vancouver Research and Development Facility	22-03-25	CI
Nirvana Life Sciences Inc. Reports Progress with Health Canada Dealer's License Application and Facility Development	22-03-21	CI

Chart Nirvana Life Sciences Inc.

Duration

Period

More charts

Nirvana Life Sciences Inc. is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The Company has selected two products for its first phase of development: a one-per-day slow release gel cap that assists transition from opioids to non-addictive pain relief therapies, and a one-per-day slow release gel cap that delivers non-addictive pain relief. Any number of therapeutic medicines and products are created from its formulations. The Company is also engaged in growing several genera and species of fungi (including rare and hybrid varieties) with a batch consistency.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NIRVANA LIFE SCIENCES INC.	+100.00%	1.41M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B